pharmaphorum3d
Pharma M&A rumour mill grinds out Mirati's name again
PRMT5 inhibitor MRTX1719 for MTAP-deleted cancers, and selective SOS1 inhibitor MRTX0902. Last year, the Financial Times also reported that there was interest in a Mirati buyout, citing Merck as ...